Format

Send to

Choose Destination
Int J Drug Policy. 2019 Apr;66:80-81. doi: 10.1016/j.drugpo.2018.11.006. Epub 2019 Feb 7.

The tripping point: The potential role of psychedelic-assisted therapy in the response to the opioid crisis.

Author information

1
Interdisciplinary Studies, University of British Columbia, 270-2357 Main Mall, H. R. MacMillan Building, Vancouver, BC, V6T 1Z4, Canada; Centre for Gender & Sexual Health Equity, 1190 Hornby Street, Vancouver, BC, V6Z 2K5, Canada.
2
British Columbia Centre on Substance Use, 400-1045 Howe St, Vancouver, BC, V6Z 2A9, Canada; School of Population and Public Health, University of British Columbia, 5804 Fairview Avenue, Vancouver, BC, V6T 1Z3, Canada.
3
British Columbia Centre on Substance Use, 400-1045 Howe St, Vancouver, BC, V6Z 2A9, Canada; Department of Medicine, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC, V6T 2A1, Canada. Electronic address: bccsu-es@bccsu.ubc.ca.

Abstract

The increasing contamination of the drug supply with illicitly manufactured fentanyl and related analogs in North America has resulted in the most severe drug-overdose crisis in history. Available pharmacotherapy options for the treatment of opioid use disorder have had limited success in curbing the current crisis, and a growing body of evidence highlights the need for innovative interventions that target underlying social-structural drivers of opioid use disorder. Re-emerging clinical research suggests that psychedelic-assisted therapy has potential as an alternative treatment for refractory substance use disorders and related comorbidities. Based on the available evidence, our viewpoint supports advancing research on the potential role of psychedelic-assisted therapy within a multifaceted response to the opioid crisis.

KEYWORDS:

Addiction treatment; Opioid crisis; Opioid use disorder; Psychedelic-assisted therapy; Psychedelics

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center